Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review

Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage, although the combination of TACE with sorafenib may theoretically benefit HCC patients in intermediate stage. Owing to the significant antiangiogenic effect of sorafenib and the limitation of TACE, it is rationa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardini, Andrea Casadei, Santini, Daniele, Aprile, Giuseppe, Silvestris, Nicola, Felli, Emanuele, Foschi, Francesco Giuseppe, Ercolani, Giorgio, Marisi, Giorgia, Valgiusti, Martina, Passardi, Alessandro, Puzzoni, Marco, Silletta, Marianna, Brunetti, Oronzo, Cardellino, Giovanni Gerardo, Frassineti, Giovanni Luca, Scartozzi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630448/
https://www.ncbi.nlm.nih.gov/pubmed/29029548
http://dx.doi.org/10.18632/oncotarget.19449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630448/
https://www.ncbi.nlm.nih.gov/pubmed/29029548
http://dx.doi.org/10.18632/oncotarget.19449

Ejemplares similares